ClinicalTrials.gg
RecruitingNCT07047482Updated Jul 10, 2025

Clinicopathological Value of p16 Expression in Colorectal Carcinoma

An observational study in Colorectal Carcinoma, sponsored by Sohag University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Sohag University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
50
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Colorectal Neoplasms with a site in Egypt — 15 open to participants now, 17 under way, 5 of them phase 3. Colorectal Neoplasms · Egypt.

Planned enrollment
20th of 23
50 · median 96
Started
2025
with 4 others
Observational
23 of 55
4 open now
Primary completion
2026-03
later than 7 of 16 live
Registered
44th of 55
by date
Lead sponsor
6 of 55
Sohag University

Among the 55 studies in Colorectal Neoplasms with a site in Egypt, this one is the 20th largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2025, is one of 23 observational ones, reaches primary completion later than 7 of the 16 other live ones, and was the 44th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 55 studies in Colorectal Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Colorectal Neoplasms with a site in Egypt, or all of them as a file.
02

Study summary

Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.

Read the detailed description

Colorectal Carcinoma is very common nowadays, with increasing need for further research.

p16 is tumor suppressor gene with a vital rule ; inactivation of p16 leads to tumor formation and progression.

50 Specimens will be collected from Pathology Department of Sohag University Hospital. Sufficient clinical and histopathological data will be attached for each case.

The previously processed formalin-fixed, paraffin-embedded tissue blocks will be used to get Hematoxylin \& Eosin stained sections to confirm the diagnosis and to detect the histopathological type, grade and stage of each tumor.

Another sliced tissue sections will be immunohistochemically stained with p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.

03

Conditions studied

  • Colorectal Carcinoma

Keywords

  • p16 Expression
  • Colorectal Carcinoma
  • Immunohistochemical study
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Fifty (50) cases of colorectal cancer will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Specimens from patients with colorectal cancer.
  2. Tissue blocks with sufficient material.
  3. Specimens with sufficient clinical data.

Exclusion criteria

Exclusion Criteria:

  1. Tissue blocks with insufficient, destroyed or necrotic material.
  2. Specimens with insufficient clinical data.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Participants

    Fifty (50) cases of colorectal cancer will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.

    Biological: Immunohistochemical staining

Interventions

  • BiologicalImmunohistochemical staining

    Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.

06

What researchers measure

Primary outcomes

  1. Evaluation of p16 Expression in Colorectal Carcinoma.

    Immunohistochemical staining of Colorectal tissues by p16 monoclonal antibody

    Time frame: 6 months

Secondary outcomes

  1. Correlation of p16 expression to different clinical and pathological parameters

    Correlation of p16 expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine
    Sohag, Recruiting, Egypt
    Recruiting
    • Magdy M Amin, Professor · Contact
    • Sherry R Azmy, Demonstrator of pathology · Contactshery.raoof@med.sohag.edu.eg · 01507557371
    • Sherry R Azmy, Demonstrator of pathology · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Not decided yet

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Mar 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 2, 2025
StartActual
May 1, 2025
Primary completionEst.
Mar 21, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07047482
Lead sponsor
Sohag University
Responsible party
Sherry Raouf Azmy (Demonstrator of pathology, Sohag University) — Principal investigator
First posted
Jul 2, 2025
Start date
May 1, 2025
Primary completion
Mar 21, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 10, 2025

Study contacts

Sherry R Azmy, Demonstrator of pathology
Contact
shery.raoof@med.sohag.edu.eg
01507557371 ext. 01207589093

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion